文献速递免疫规划慢病防控与筛查

肾移植受者对13价肺炎球菌结合疫苗的体液免疫应答

Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
PubMed 文献 · Vaccine · 2020-03-13

研究对49例肾移植受者接种13价肺炎球菌结合疫苗(PCV13),采用调理吞噬杀菌试验(OPA)和多种ELISA检测接种前及接种后1个月、12个月的抗体应答。结果显示接种后1个月13/13血清型OPA几何平均滴度显著升高,12个月时10/13血清型显著升高;53%受者在1个月达到疫苗应答标准,45%在12个月达到。肾移植受者接种PCV13后存在显著体液应答,但功能性抗体应答不如健康成人强烈。

要点

  • 49例肾移植受者接种PCV13后1个月13/13血清型OPA几何平均滴度显著升高。
  • 接种后1个月53%受者达到OPA滴度≥1:8的疫苗应答标准,12个月为45%。
  • 接种后1个月年龄匹配健康参考人群的中位OPA滴度比肾移植受者高5至10倍。

核心结论

  • 肾移植受者接种PCV13后表现出显著的体液免疫应答,但功能性抗体应答不如健康成人强烈。

研究设计与样本

  • 49例肾移植受者接种PCV13,于接种前及接种后1个月和12个月采用经验证的调理吞噬杀菌试验(OPA)、全局抗肺炎球菌荚膜多糖(anti-PCP)IgG、IgG2、IgM和IgA ELISA检测,部分患者另做血清型特异性抗PCP WHO参考ELISA。

主要发现

  • OPA几何平均滴度在接种后1个月对13/13血清型显著升高,在接种后12个月对10/13血清型显著升高。
  • 以达到OPA滴度≥1:8定义为疫苗应答,中位数有9/13血清型达到应答;53%受者在1个月达到疫苗应答标准,45%在12个月达到。
  • 接种后1个月,年龄匹配健康参考人群的中位OPA滴度比肾移植受者高5至10倍。
  • OPA滴度与全局及血清型特异性抗PCP IgG ELISA结果强相关。
  • 较低的OPA滴度与白蛋白尿、接种与移植间隔小于12个月、年龄及霉酚酸酯治疗显著相关(p < 0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination against S. pneumoniae is recommended by national guidelines. Moderate immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) has been reported in adult kidney transplant recipients (KTR). This study further defines the immunogenicity of PCV13 in this cohort. METHODS: 49 KTR were immunized with PCV13. A validated opsonophagocytic killing assay (OPA), a global anti-pneumococcal capsular polysaccharide (anti-PCP) IgG, IgG2, IgM and IgA ELISA, and - for selected patients - a serotype specific anti-PCP WHO reference ELISA were performed pre-vaccination and at month 1 and 12 post-vaccination. RESULTS: Geometric mean OPA titers increased significantly for 13/13 serotypes at month 1 and for 10/13 serotypes at month 12 post-vaccination. Vaccine response defined as an OPA titer ≥1:8 was reached in 9/13 serotypes (median). 53% reached the vaccine response criteria at month 1 and 45% at month 12. At month 1 after vaccination, the median OPA titer in an age-group matched healthy reference population was 5- to 10-fold higher than in KTR. OPA titers correlated strongly with results to the global and serotype specific anti-PCP IgG ELISA. Lower OPA titers significantly (p < 0.05) correlated with albuminuria, an interval between vaccination and transplantation <12 months, age and treatment with mycophenolate mofetil. Global IgG, IgG2, IgM and IgA, as well as serotype specific anti-PCP antibody concentrations (12/13 serotypes) increased significantly at month 1 and 12 post-vaccination. CONCLUSIONS: Kidney transplant recipients show a significant humoral response after vaccination with PCV13. Functional antibody response exists, but is not as vigorous as in healthy adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Oesterreich S, Lindemann M, Goldblatt D, et al. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Vaccine. 2020. PMID: 32178906. doi:10.1016/j.vaccine.2020.02.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。